Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Oncimmune Holdings plc (ONC.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
185.00+7.50 (+4.23%)
At close: 4:35PM BST
Advertisement

Oncimmune Holdings plc

D6 Building
1 Thane Road
Nottingham NG90 6BH
United Kingdom
44 1157 840 500
http://www.oncimmune.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Dr. Adam Mark Hill Ph.D.CEO & Director385kN/A1980
Mr. Matthew HallChief Financial OfficerN/AN/AN/A
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCPChief Scientific OfficerN/AN/AN/A
Ms. Cléa RosenfeldHead of Investor RelationsN/AN/AN/A
Mr. Ron KirschnerGen. Counsel & Company Sec.N/AN/AN/A
Dr. James R. Jett M.D.Chief Medical Officer of USN/AN/AN/A
Mr. Maarten BrusseChief Commercial Officer of AsiaN/AN/AN/A
Mr. Shane SmithSr. VP of Market Access & Reimbursement Oncimmune (Usa)N/AN/AN/A
Mr. Cameron BarnardChief Bus. OfficerN/AN/AN/A
Mr. Andrew Millet BA, FCA, MBAExec.N/AN/A1967
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Corporate Governance

Oncimmune Holdings plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement